Open Access<p>Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial</p>
Author(s) -
Ming Zhan,
Haifeng Zheng,
Yang Yu,
Zhiyao He,
Ting Xu,
Qiu Li
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s283169
Subject(s) - olaparib , medicine , brca mutation , oncology , pancreatic cancer , placebo , maintenance therapy , parp inhibitor , cancer , ovarian cancer , chemotherapy , pathology , biology , genetics , alternative medicine , polymerase , gene , poly adp ribose polymerase
The phase III POLO trial demonstrated that olaparib as maintenance therapy for metastatic pancreatic cancer patients with a germline BRCA mutation had greater efficacy than placebo, but maintenance olaparib places an economic burden on patients. This study evaluated the cost-effectiveness of olaparib as maintenance therapy based on the POLO trial (NCT02184195).